Form 4: BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, Reports Stock Transactions
SEC Form 4
Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.
Summary
- On September 14, 2024, Frank Yocca, the Chief Scientific Officer of BioXcel Therapeutics, acquired 521 shares of common stock through the vesting of restricted stock units (RSUs) and disposed of an unspecified number of shares.
- On September 15, 2024, Yocca acquired 563 shares of common stock through RSU vesting and disposed of an unspecified number of shares.
- On September 16, 2024, Yocca disposed of 355 shares of common stock at a price of $0.6893 per share.
- Following these transactions, Yocca directly owns 14,203 shares of BioXcel Therapeutics common stock and 5,625 restricted stock units.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It doesn't necessarily reflect the overall health or prospects of BioXcel Therapeutics but offers insight into the actions of its Chief Scientific Officer.
Key Dates
| Date | Description |
|---|---|
| 2022-03-14 | Reporting Person was granted 8,337 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 14, 2022 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter. |
| 2023-03-15 | Reporting Person was granted 9,000 RSUs, vesting as to 25% of the total number of RSUs on the first anniversary of March 15, 2023 and as to 6.25% of the total number of RSUs at the end of each successive three-month period thereafter. |
| 2023-12-14 | Rule 10b5-1 trading plan adopted. |
| 2024-09-14 | Acquisition of 521 shares of common stock through RSU vesting. |
| 2024-09-15 | Acquisition of 563 shares of common stock through RSU vesting. |
| 2024-09-16 | Sale of 355 shares of common stock at $0.6893 per share. |
| 2024-09-17 | Date of Form 4 filing. |
Keywords
BioXcel Therapeutics, BTAI, Frank Yocca, Chief Scientific Officer, Form 4, Stock Transactions, Restricted Stock Units, RSU, Beneficial Ownership, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.